西西
Lv31
340 积分
2025-08-27 加入
-
The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020
4天前
已完结
-
Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature Review
4天前
已完结
-
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
18天前
已完结
-
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study
19天前
已完结
-
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
19天前
已完结
-
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
19天前
已完结
-
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
19天前
已完结
-
Use of Single-Arm Trials in FDA Approvals of Treatments in Relapsed or Refractory B-Cell Lymphoma
28天前
已关闭
-
Comparison of Single-Arm vs. Randomized Phase II Clinical Trials: A Bayesian Approach
1个月前
已完结
-
Use of Single-Arm Trials in FDA Approvals of Treatments in Relapsed or Refractory B-Cell Lymphoma
1个月前
已关闭